Johnson & Johnson (JNJ) is scheduled to report Q2 2026 earnings before market open tomorrow (15 July), with analysts expecting the healthcare giant to extend its recent streak of earnings beats. The setup for JNJ shares shows clear outperformance, with a pause on momentum leading into the print.
The company has topped consensus EPS estimates in each of its last two quarters, delivering an average surprise of 1.18% and reinforcing its reputation as a stable large-cap pharma play in a sector that spans volatile biotech names and established dividend payers.
Wall Street is looking for an EPS of $2.85, based on 17 analyst estimates ranging from $2.65 to $3.00. That would represent a year-on-year increase from the $2.77 earned in Q2 2025. Revenue is expected to reach approximately $25.06 billion, up 5.5% Y/Y.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The company has demonstrated consistent execution in recent quarters. In Q1 2026, JNJ posted actual EPS of $2.70 against a consensus estimate of $2.67, representing a 1.12% beat. The prior quarter saw EPS of $2.46 versus the $2.43 consensus, a 1.23% surprise.
What to watch
Markets will be watching several key areas when the numbers land on Wednesday morning.
Pharma segment performance remains the most important revenue driver for the business. Margin trends and operating efficiency will also come under scrutiny, particularly in a period where large-cap healthcare names are being compared for their ability to deliver steady earnings growth without the volatility seen in smaller biotech stocks.
Forward guidance will be usually be more decisive as far as share price direction following the print, and will be watched for any signals on demand trends, pricing power, and cost management through the second half of 2026. Any commentary on pipeline developments or regulatory updates would add colour to the outlook.
JNJ’s dividend track record is another point of focus. The company has raised its payout for 64 consecutive years, making it a fixture in retirement and income portfolios. JNJ is an example of a dividend grower that compounds payouts over time, contrasting it with higher-yielding but less reliable income strategies.
What to expect from JNJ
JNJ shares have been a huge outperformer over the past year, adding 64.37% before dividends, more than triple the S&P 500’s 19.89% gain on the period, and double that of Nvidia.
The share price has come down a few percent off the new highs printed last week, with markets pricing a move of 3.8% on the week for JNJ. Tests of $270 or $250 cannot be discounted this week.
